Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M

Travere Therapeutics, Inc.

2025-Q2 EPS reported -$0.61 vs consensus -$0.30 ▼ miss (-100.9%)

U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.
Total revenue $114.4M including $17.5M milestone from CSL Vifor; net product sales total $94.8M.
Net loss $12.8M ($0.14/share) vs $70.4M loss ($0.91/share) in Q2 2024; non-GAAP net income $11.9M.
Cash $319.5M; sNDA for FSGS accepted with PDUFA Jan 13, 2026; IgAN REMS modification PDUFA Aug 28, 2025.
R&D expense $49.4M (-9% YoY); SG&A expense $76.2M (+18% YoY).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.